The present invention provides compounds of formula (I)
##STR1##
as well as the use of such compounds in pharmaceutical compositions and methods
of treatment.
The compounds described herein represent a class of TAFIa inhibitors suitable
for use in treating conditions such as thrombosis, atherosclerosis, adhesions,
dermal scarring, cancer, fibrotic conditions, inflammatory diseases and those conditions
which benefit from maintaining or enhancing bradykinin levels in the body.
